Huabo Biopharm

aka Shanghai Huaota Biopharmaceutical, Huaota Biopharm, 华奥泰生物

Huabo Biopharm is a Shanghai antibody company whose bispecific HB0036 blocks PD-L1 and TIGIT at once so that exhausted T cells can attack the tumour.

Huabo Biopharm (Shanghai Huaota Biopharmaceutical) is a Shanghai-based developer of monoclonal and bispecific antibodies. Its oncology pipeline includes HB0036, a bispecific antibody against PD-L1 and TIGIT that is in phase 1/2 trials in advanced solid tumours including non-small cell lung cancer, alongside HB0025 (PD-L1 and VEGF) and HB0017, an IL-17A antibody for psoriasis.

Headquarters

Shanghai, CN

Scorecard

All companies

#359of 1181 companies, score 9

phase 1/2 +1
targets +4
modalities +2
registry trials +2

0 approved, 0 in phase 3, 1 earlier, 2 targets, 1 registry studies. Formula on the scorecards page.

Type

biotech

Products

1top

Phase 2bifunctional antibody (anti-PD-L1/anti-TIGIT, per the sponsor's description; form not stated in the registry record)

HB0036

HB0036 is an experimental investigational agent whose form is not stated in the registry from Shanghai Huaota Biopharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-L1 and TIGIT.

Connected